Telaprevir Under Study for HIV/HCV Coinfection
The investigational hepatitis C virus (HCV) protease inhibitor telaprevir -- the furthest along of the new directly targeted antiviral agents -- is now being tested in HIV/HCV coinfected individuals. The drug has demonstrated good antiviral activity in combination with pegylated interferon plus ribavirin in clinical trials of people with hepatitis C alone, and developer Vertex Pharmaceuticals plans to request FDA approval in the second half of this year. For further information, see "Open Clinical Trials."
Liz Highleyman (firstname.lastname@example.org) is a freelance medical writer based in San Francisco.View Full Article
Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)